Cellular prostatic acid phosphatase: A protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer

Suresh Veeramani, Ta Chun Yuan, Siu Ju Chen, Fen Fen Lin, Juliette E. Petersen, Syed Shaheduzzaman, Shiv Srivastava, Richard G MacDonald, Ming-Fong Lin

Research output: Contribution to journalReview article

72 Citations (Scopus)

Abstract

Human prostatic acid phosphatase (PAcP) was used as a valuable surrogate marker for monitoring prostate cancer prior to the availability of prostate-specific antigen (PSA). Even though the level of PAcP is increased in the circulation of prostate cancer patients, its intracellular level and activity are greatly diminished in prostate cancer cells. Recent advances in understanding the function of the cellular form of PAcP (cPAcP) have shed some light on its role in prostate carcinogenesis, which may have potential applications for prostate cancer therapy. It is now evident that cPAcP functions as a neutral protein tyrosine phosphatase (PTP) in prostate cancer cells and dephosphorylates HER-2/ErbB-2/Neu (HER-2: human epidermal growth factor receptor-2) at the phosphotyrosine (p-Tyr) residues. Dephosphorylation of HER-2 at its p-Tyr residues results in the down-regulation of its specific activity, which leads to decreases in growth and tumorigenicity of those cancer cells. Conversely, decreased cPAcP expression correlates with hyperphosphorylation of HER-2 at tyrosine residues and activation of downstream extracellular signal-regulated kinase (ERK)/mitogen activated protein kinase (MAPK) signaling, which results in prostate cancer progression as well as androgen-independent growth of prostate cancer cells. These in vitro results on the effect of cPAcP on androgen-independent growth of prostate cancer cells corroborate the clinical findings that cPAcP level is greatly decreased in advanced prostate cancer and provide insights into one of the molecular mechanisms involved in prostate cancer progression. Results from experiments using xenograft animal models further indicate a novel role of cPAcP as a tumor suppressor. Future studies are warranted to clarify the use of cPAcP as a therapeutic agent in human prostate cancer patients.

Original languageEnglish (US)
Pages (from-to)805-822
Number of pages18
JournalEndocrine-Related Cancer
Volume12
Issue number4
DOIs
StatePublished - Dec 1 2005

Fingerprint

Protein Tyrosine Phosphatases
Androgens
Prostatic Neoplasms
Phosphotyrosine
prostatic acid phosphatase
Growth
Extracellular Signal-Regulated MAP Kinases
Prostate-Specific Antigen
Mitogen-Activated Protein Kinases
Heterografts
Prostate
Neoplasms
Carcinogenesis
Down-Regulation
Animal Models
Biomarkers

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research

Cite this

Cellular prostatic acid phosphatase : A protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. / Veeramani, Suresh; Yuan, Ta Chun; Chen, Siu Ju; Lin, Fen Fen; Petersen, Juliette E.; Shaheduzzaman, Syed; Srivastava, Shiv; MacDonald, Richard G; Lin, Ming-Fong.

In: Endocrine-Related Cancer, Vol. 12, No. 4, 01.12.2005, p. 805-822.

Research output: Contribution to journalReview article

Veeramani, Suresh ; Yuan, Ta Chun ; Chen, Siu Ju ; Lin, Fen Fen ; Petersen, Juliette E. ; Shaheduzzaman, Syed ; Srivastava, Shiv ; MacDonald, Richard G ; Lin, Ming-Fong. / Cellular prostatic acid phosphatase : A protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. In: Endocrine-Related Cancer. 2005 ; Vol. 12, No. 4. pp. 805-822.
@article{5d516cd6778f47dba75dbd0de07b7161,
title = "Cellular prostatic acid phosphatase: A protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer",
abstract = "Human prostatic acid phosphatase (PAcP) was used as a valuable surrogate marker for monitoring prostate cancer prior to the availability of prostate-specific antigen (PSA). Even though the level of PAcP is increased in the circulation of prostate cancer patients, its intracellular level and activity are greatly diminished in prostate cancer cells. Recent advances in understanding the function of the cellular form of PAcP (cPAcP) have shed some light on its role in prostate carcinogenesis, which may have potential applications for prostate cancer therapy. It is now evident that cPAcP functions as a neutral protein tyrosine phosphatase (PTP) in prostate cancer cells and dephosphorylates HER-2/ErbB-2/Neu (HER-2: human epidermal growth factor receptor-2) at the phosphotyrosine (p-Tyr) residues. Dephosphorylation of HER-2 at its p-Tyr residues results in the down-regulation of its specific activity, which leads to decreases in growth and tumorigenicity of those cancer cells. Conversely, decreased cPAcP expression correlates with hyperphosphorylation of HER-2 at tyrosine residues and activation of downstream extracellular signal-regulated kinase (ERK)/mitogen activated protein kinase (MAPK) signaling, which results in prostate cancer progression as well as androgen-independent growth of prostate cancer cells. These in vitro results on the effect of cPAcP on androgen-independent growth of prostate cancer cells corroborate the clinical findings that cPAcP level is greatly decreased in advanced prostate cancer and provide insights into one of the molecular mechanisms involved in prostate cancer progression. Results from experiments using xenograft animal models further indicate a novel role of cPAcP as a tumor suppressor. Future studies are warranted to clarify the use of cPAcP as a therapeutic agent in human prostate cancer patients.",
author = "Suresh Veeramani and Yuan, {Ta Chun} and Chen, {Siu Ju} and Lin, {Fen Fen} and Petersen, {Juliette E.} and Syed Shaheduzzaman and Shiv Srivastava and MacDonald, {Richard G} and Ming-Fong Lin",
year = "2005",
month = "12",
day = "1",
doi = "10.1677/erc.1.00950",
language = "English (US)",
volume = "12",
pages = "805--822",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "Society for Endocrinology",
number = "4",

}

TY - JOUR

T1 - Cellular prostatic acid phosphatase

T2 - A protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer

AU - Veeramani, Suresh

AU - Yuan, Ta Chun

AU - Chen, Siu Ju

AU - Lin, Fen Fen

AU - Petersen, Juliette E.

AU - Shaheduzzaman, Syed

AU - Srivastava, Shiv

AU - MacDonald, Richard G

AU - Lin, Ming-Fong

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Human prostatic acid phosphatase (PAcP) was used as a valuable surrogate marker for monitoring prostate cancer prior to the availability of prostate-specific antigen (PSA). Even though the level of PAcP is increased in the circulation of prostate cancer patients, its intracellular level and activity are greatly diminished in prostate cancer cells. Recent advances in understanding the function of the cellular form of PAcP (cPAcP) have shed some light on its role in prostate carcinogenesis, which may have potential applications for prostate cancer therapy. It is now evident that cPAcP functions as a neutral protein tyrosine phosphatase (PTP) in prostate cancer cells and dephosphorylates HER-2/ErbB-2/Neu (HER-2: human epidermal growth factor receptor-2) at the phosphotyrosine (p-Tyr) residues. Dephosphorylation of HER-2 at its p-Tyr residues results in the down-regulation of its specific activity, which leads to decreases in growth and tumorigenicity of those cancer cells. Conversely, decreased cPAcP expression correlates with hyperphosphorylation of HER-2 at tyrosine residues and activation of downstream extracellular signal-regulated kinase (ERK)/mitogen activated protein kinase (MAPK) signaling, which results in prostate cancer progression as well as androgen-independent growth of prostate cancer cells. These in vitro results on the effect of cPAcP on androgen-independent growth of prostate cancer cells corroborate the clinical findings that cPAcP level is greatly decreased in advanced prostate cancer and provide insights into one of the molecular mechanisms involved in prostate cancer progression. Results from experiments using xenograft animal models further indicate a novel role of cPAcP as a tumor suppressor. Future studies are warranted to clarify the use of cPAcP as a therapeutic agent in human prostate cancer patients.

AB - Human prostatic acid phosphatase (PAcP) was used as a valuable surrogate marker for monitoring prostate cancer prior to the availability of prostate-specific antigen (PSA). Even though the level of PAcP is increased in the circulation of prostate cancer patients, its intracellular level and activity are greatly diminished in prostate cancer cells. Recent advances in understanding the function of the cellular form of PAcP (cPAcP) have shed some light on its role in prostate carcinogenesis, which may have potential applications for prostate cancer therapy. It is now evident that cPAcP functions as a neutral protein tyrosine phosphatase (PTP) in prostate cancer cells and dephosphorylates HER-2/ErbB-2/Neu (HER-2: human epidermal growth factor receptor-2) at the phosphotyrosine (p-Tyr) residues. Dephosphorylation of HER-2 at its p-Tyr residues results in the down-regulation of its specific activity, which leads to decreases in growth and tumorigenicity of those cancer cells. Conversely, decreased cPAcP expression correlates with hyperphosphorylation of HER-2 at tyrosine residues and activation of downstream extracellular signal-regulated kinase (ERK)/mitogen activated protein kinase (MAPK) signaling, which results in prostate cancer progression as well as androgen-independent growth of prostate cancer cells. These in vitro results on the effect of cPAcP on androgen-independent growth of prostate cancer cells corroborate the clinical findings that cPAcP level is greatly decreased in advanced prostate cancer and provide insights into one of the molecular mechanisms involved in prostate cancer progression. Results from experiments using xenograft animal models further indicate a novel role of cPAcP as a tumor suppressor. Future studies are warranted to clarify the use of cPAcP as a therapeutic agent in human prostate cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=29144502951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29144502951&partnerID=8YFLogxK

U2 - 10.1677/erc.1.00950

DO - 10.1677/erc.1.00950

M3 - Review article

C2 - 16322323

AN - SCOPUS:29144502951

VL - 12

SP - 805

EP - 822

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 4

ER -